SPECIFICATION AMENDMENTS

(Insertions indicated by underline; deletions indicated by strikethrough)

Please add a paragraph beginning at page 1, line 3, with the following:

This application is a continuation of U.S. patent application no. 09/171,086, filed January 22, 1999, now abandoned, which is the national phase of international patent application no. PCT/US97/06632, filed April 21, 1997, now lapsed, which claims the benefit of U.S. provisional patent application no. 60/015,893, filed April 22, 1996, now lapsed.

Replace the paragraph beginning at page 5, line 7, with the following:

Fig. 1A-1E: Compares the effect of repetitive immunization of the recombinant vaccine vectors on tumor growth and long-term survival in BALB/c mice intravenously challenged with 10^5 CT26.CL25 tumor cells to establish pulmonary metastases. The mice were primed with various vectors 3 days post-intravenous challenge and then boosted with the same amount and ~~array of~~ vectors 17 days after tumor inoculation. **Fig. 1A** – data of mice primed with no immunogen (None) and later boosted by either no immunogen, 10^7 PFU of rVV expressing β-gal (VJS6), 10^7 PFU of rFPV expressing β-gal (rFPV) or 10μg of pCMV/ β-gal (DNA). **Fig. 1B** – data of mice primed with VJS6 and later boosted by either no immunogen, VJS6, rFPV or DNA. **Fig. 1C** – data of mice primed with rFPV and later boosted by either no immunogen, VJS6, rFPV or DNA. **Fig. 1D** – data of mice primed with DNA and later boosted by either no immunogen, VJS6, rFPV or DNA. **Fig. 1E** – data of mice primed with no immunogen, VJS6, rFPV or DNA and then boosted with DNA. The no treatment group (None – None) is shown in all graphs of **Fig. 1** as a control group.